1027534-10-6

Basic information

• Product Name: (S)-5-Aminomethyl-3-(3-methyl-4-morpholin-4-yl-phenyl)-oxazolidin-2-one
• CAS NO: 1027534-10-6
• Molecular Weight: 291.35
• Mol File: 1027534-10-6.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (S)-5-Aminomethyl-3-(3-methyl-4-morpholin-4-yl-phenyl)-oxazolidin-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-5-Aminomethyl-3-(3-methyl-4-morpholin-4-yl-phenyl)-oxazolidin-2-one(1027534-10-6)
• EPA Substance Registry System: (S)-5-Aminomethyl-3-(3-methyl-4-morpholin-4-yl-phenyl)-oxazolidin-2-one(1027534-10-6)

Safety Data

• Hazardous Substances Data: 1027534-10-6(Hazardous Substances Data)

Upstream product

• 1027184-22-0 Methanesulfonic acid (R)-3-(3-methyl-4-morpholin-4-yl-phenyl)-2-oxo-oxazolidin-5-ylmethyl ester 
• 1026622-97-8 (R)-5-Hydroxymethyl-3-(3-methyl-4-morpholin-4-yl-phenyl)-oxazolidin-2-one 
• 112900-82-0 3-methyl-4-(morpholin-4-yl)aniline 
• 1026410-10-5 (R)-5-Azidomethyl-3-(3-methyl-4-morpholin-4-yl-phenyl)-oxazolidin-2-one 

Downstream Products

• 1027386-00-0 (R)-5-Isothiocyanatomethyl-3-(3-methyl-4-morpholin-4-yl-phenyl)-oxazolidin-2-one 

Relevant articles and documents

Structure-activity relationship (SAR) studies on oxazolidinone antibacterial agents. 2.1) Relationship between lipophilicity and antibacterial activity in 5-thiocarbonyl oxazolidinones

5-Thiourea and 5-dithiocarbamate oxazolidinones were synthesized as a continuation of research on 5-thiocarbonyl oxazolidinone antibacterial agents considering the hydrophobic parameters of the molecule. The structure-activity relationship (SAR) study revealed that the antibacterial activity on 5-thiocarbonyl oxazolidinones was significantly affected by the lipophilicity, especially the calculated log P value and the balance between 5-hydrophilic (or hydrophobic) substituent and hydrophobic (or hydrophilic) substituents on the benzene ring. Some of 5-thiocarbonyl oxazolidinones were found to have good in vitro antibacterial activity against gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE).